---
schema_version: "secwatch.filing_event.v1"
accession: "0001295947-23-000014"
form_type: "8-K"
ticker: "PBH"
cik: "0001295947"
company_name: "Prestige Consumer Healthcare Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T20:57:06.609979+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prestige Consumer Healthcare reports record FY23 revenue $1.1277B; guides FY24 EPS $4.27-$4.32

## Summary
- Q4 revenue $285.9M (+7.1% YoY, +8.0% organic); adjusted EPS $1.07 vs $0.91 prior year.
- Full year FY23 revenue $1.1277B (record); net loss $82.3M on impairments; adjusted EPS $4.21.
- FY24 guidance: revenue $1.135-$1.140B, diluted EPS $4.27-$4.32, free cash flow $240M+.
- Board authorized $25M share repurchase through May 2024.
- Covenant leverage ratio 3.3x; new long-term target below 3.0x.

## SEC filing metadata
- accession: 0001295947-23-000014
- form_type: 8-K
- ticker: PBH
- cik: 0001295947
- company_name: Prestige Consumer Healthcare Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1295947/000129594723000014/0001295947-23-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1295947/000129594723000014/pbh-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001295947-23-000014
- JSON: https://secwatch.observer/filing/0001295947-23-000014.json
- Plain text: https://secwatch.observer/filing/0001295947-23-000014.txt

## Key facts
- Earnings Releases
  Prestige Consumer Healthcare Inc. reported the fiscal year ended March 31, 2023 results: revenue $1,127.7 million, net income net loss of $82.3 million, EPS diluted loss per share of $1.65.
  - Period: the fiscal year ended March 31, 2023
  - Revenue: $1,127.7 million
  - Net income: net loss of $82.3 million
  - EPS: diluted loss per share of $1.65
  - Result: reported results
  source text: Reported revenues for the fiscal year 2023 totaled $1,127.7 million, an increase of 3.8%, compared to revenues of $1,086.8 million for the fiscal year 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1295947/000129594723000014/0001295947-23-000014-index.htm
- Earnings Releases
  Prestige Consumer Healthcare Inc. reported Fiscal 2024 results: revenue $1,135 to $1,140 Million, EPS $4.27 to $4.32. Guidance initiated.
  - Period: Fiscal 2024
  - Revenue: $1,135 to $1,140 Million
  - EPS: $4.27 to $4.32
  - Guidance: initiated
  - Result: guidance update
  source text: Initial Full-Year Fiscal 2024 Revenue and EPS Expectation of $1,135 to $1,140 Million and $4.27 to $4.32, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1295947/000129594723000014/0001295947-23-000014-index.htm
- Earnings Releases
  Prestige Consumer Healthcare Inc. reported the fourth quarter ended March 31, 2023 results: revenue $285.9 million, net income net loss of $240.6 million, EPS diluted loss per share of $4.83.
  - Period: the fourth quarter ended March 31, 2023
  - Revenue: $285.9 million
  - Net income: net loss of $240.6 million
  - EPS: diluted loss per share of $4.83
  - Result: reported results
  source text: Reported revenues in the fourth quarter of fiscal 2023 of $285.9 million increased 7.1% from $266.9 million in the fourth quarter of fiscal 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1295947/000129594723000014/0001295947-23-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.